Editorial
Understanding peripartum cardiomyopathy, 2008

https://doi.org/10.1016/j.ijcard.2008.03.076Get rights and content

Abstract

Although the exact etiology of peripartum cardiomyopathy (PPCM) is still unknown, the inciting factor(s) appears to initiate an inflammatory cardiomyopathy that transitions to an autoimmune or immune dysfunctional process leading to severe heart failure in the peripartum. Early diagnosis and effective treatment, including diuretics, ACE-inhibitors, and beta-blockers, leads to improvement in most and eventual left ventricular systolic recovery in over half of patients. Additional evaluations and potential non-conventional treatments for non-responders may include research protocol use of apheresis, intravenous gamma globulin, immunoadsorption, other immunomodulation therapy, and possible anti-viral therapy.

References (12)

There are more references available in the full text version of this article.

Cited by (14)

  • Cardiomyopathy — An approach to the autoimmune background

    2017, Autoimmunity Reviews
    Citation Excerpt :

    Reflecting unpublished data from an animal study, it was suggested that the future focus of Chagas' cardiomyopathy treatment should focus on efforts to restore the immunological tolerance to self-antigens which should include trypanocidal drug treatment and an immunotherapeutic strategy such as IVIG [223]. Also, IVIG treatment was mentioned as an option for peripartum cardiomyopathy [205]. In agreement with this, 6 women vs. 11 conventionally-treated patients with peripartum cardiomyopathy demonstrated benefits as expressedby improved LVED [224].

  • Recovery from severe heart failure following peripartum cardiomyopathy

    2009, International Journal of Gynecology and Obstetrics
    Citation Excerpt :

    Additional evaluations may include identification of anticardiac antibodies, cardiac magnetic resonance imaging, and endomyocardial biopsy to include immunohistochemical staining and polymerase chain reaction testing for viral RNA/DNA. These may lead to additional treatment modalities on a research protocol basis, such as apheresis or other immunoabsorption, or other immunomodulations including intravenous gamma globulin or antiviral treatment [10]. It is important to appreciate the overlap in initial echocardiographic parameters of LVEF and LV size when comparing outcomes.

  • Peripartum cardiomyopathy-A case report

    2015, Biomedical and Pharmacology Journal
View all citing articles on Scopus
View full text